Teva Continues To Position Itself For Overseas Opportunities
The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17
You may also be interested in...
In contrast to Big Pharma’s doldrums, generics manufacturer Teva had a banner year in 2008 – and expects a strong follow up in 2009.
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change
TOKYO - Japanese drug maker Kowa said Sept. 24 that it had signed a definitive agreement with Israel generic manufacturer Teva Pharmaceutical to share a 50-50 stake in a generic manufacturer in Japan to take advantage of a growing Japanese generics market